Imagine a drug that’s been saving lives for decades, yet its full potential has remained hidden—until now. A groundbreaking discovery has revealed that hydralazine, a 70-year-old blood pressure medication, may also hold the key to stopping aggressive brain tumor growth. This unexpected finding not only sheds light on how the drug works at a molecular level but also uncovers a surprising link between hypertension and brain cancer. But here’s where it gets even more fascinating: could this old drug be the new frontier in cancer treatment? Let’s dive in.
For over seven decades, hydralazine has been a cornerstone in medicine, primarily used to combat life-threatening high blood pressure, especially in pregnant women with preeclampsia. Despite its widespread use, the exact mechanism behind its effectiveness has remained a mystery—until a team led by researchers at the University of Pennsylvania cracked the code. Their study, published in Science Advances, not only explains how hydralazine works but also highlights its potential to treat one of the most aggressive forms of brain cancer, glioblastoma.
And this is the part most people miss: Hydralazine’s ability to lower blood pressure isn’t just about relaxing blood vessels; it’s about blocking a specific enzyme called 2-aminoethanethiol dioxygenase (ADO). This enzyme acts like an oxygen alarm, signaling blood vessels to constrict when oxygen levels drop. By binding to and blocking ADO, hydralazine effectively ‘mutes’ this alarm, allowing blood vessels to relax and blood pressure to drop. But the real surprise? This same mechanism may also starve brain tumors of their ability to survive in low-oxygen environments.
Kyosuke Shishikura, a physician-scientist at the University of Pennsylvania, explains, ‘Hydralazine is a relic from a ‘pre-target’ era of drug discovery, where treatments were developed based on observed effects rather than a deep understanding of their biology. Now, we’ve uncovered the molecular magic behind it.’ This discovery not only improves the drug’s safety and efficacy but also opens doors to new treatments for both maternal health and brain cancer.
Here’s the controversial part: While hydralazine has been a lifesaver for generations, its potential in cancer treatment raises questions. Could this drug, traditionally used for cardiovascular health, revolutionize oncology? And if so, why hasn’t this connection been explored sooner? Megan Matthews, a collaborator on the study, points out, ‘Preeclampsia has disproportionately affected Black mothers in the U.S., including in my own family. Understanding hydralazine’s mechanism could lead to safer treatments for these women. But its application in brain cancer? That’s a game-changer.’
The team’s research revealed that the ADO pathway, which hydralazine targets, plays a dual role: it regulates blood vessel constriction and helps tumor cells survive in low-oxygen conditions. By disrupting this pathway, hydralazine induces ‘senescence’ in glioblastoma cells, essentially putting them into a dormant state without causing inflammation or resistance—a stark contrast to traditional chemotherapy.
But here’s the bigger question: If hydralazine can do this, what other old drugs are hiding untapped potential? Matthews is already exploring this, aiming to uncover more unusual links between established treatments and new diseases. ‘It’s rare for a cardiovascular drug to teach us something about the brain,’ she says, ‘but that’s exactly what we’re after—those unexpected connections that could lead to breakthroughs.’
The next step? Developing more targeted ADO inhibitors that can cross the blood-brain barrier effectively, hitting tumor tissue while sparing healthy cells. This could pave the way for safer, more effective treatments for both preeclampsia and brain cancer.
So, what do you think? Is hydralazine’s dual role a medical marvel or a missed opportunity? Could other long-standing drugs hold similar secrets? Share your thoughts in the comments—let’s spark a conversation about the future of medicine.
